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Available online 17 April 2016Morphine and P2Y12 receptor inhibitors are both recommended in patients with acute myocardial infarction.
Morphine may impede gastrointestinal absorption of several oral drugs including P2Y12 platelet receptor
inhibitors.
The aim of this review was to critically discuss drug–drug interactions between oral P2Y12 receptor inhibitors
and morphine according to currently available knowledge based on the ﬁndings of experimental, observational
and randomized clinical studies.
The morphine–clopidogrel pharmacodynamic interaction has been observed in numerous trials and it has been
proposed as an explanation for the negative impact of morphine on the clinical outcomes in patients with acute
coronary syndromes. An analogous morphine interaction with ticagrelor and prasugrel was found in several
observational studies and ﬁnally proven in randomized trials in healthy volunteers and acute myocardial in-
farction patients.
Morphine delays and attenuates exposure and antiplatelet action of oral P2Y12 receptor inhibitors in patients
withmyocardial infarction. Although this interactionmay have potentially harmful consequences, routine avoid-
ance of morphine cannot be recommended until clinically powered trials are completed.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Drug–drug interaction1. Background
Dual antiplatelet treatment with one of the P2Y12 receptor inhibi-
tors and aspirin is a pivotal therapy in patients with acute coronary syn-
dromes (ACS) [1–4]. According to the current guidelines ticagrelor and
prasugrel are preferred in ACS patients undergoing percutaneous coro-
nary intervention (PCI) [3,4].
The rationale formorphine use in patients with acute ischemic chest
pain is an expected favorable disease modiﬁcation [5–7]. The current
guidelines for the management of patients with acute myocardial
infarction (AMI) continue to recommend intravenous (IV) morphineof Clinical Medicine, Collegium
Curie Street, 85-094 Bydgoszcz,
land Ltd. This is an open access articlas the drug of choice for pain relief [3,4]. However, there have never
been any randomized clinical trials evaluating the efﬁcacy and safety
of morphine in this population, so this recommendation is based solely
on expert consensus, not on clinical trial evidence.
Moreover, due to its pharmacological properties, particularly its im-
pact on the gastrointestinal tract, morphine may impede absorption
of several orally administered drugs including P2Y12 platelet receptor
inhibitors [8].
The aim of this review was to critically discuss drug–drug interac-
tions between oral P2Y12 inhibitors and morphine according to cur-
rently available knowledge based on the ﬁndings of experimental as
well as observational and randomized clinical studies. A searchwas con-
ducted by two independent investigators (J.K. and A.K.) using PubMed,
CENTRAL andGoogle Scholar databases. No timeor language limitations
were applied. Proceedings from the Scientiﬁc Sessions of the American
College of Cardiology (http://www.acc.org), AmericanHeart Association
(http://www.heart.org), European Society of Cardiology (http://www.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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applied: “morphine” and “clopidogrel”, “morphine” and “prasugrel”,
“morphine” and “ticagrelor”, “morphine” and “P2Y12 inhibitors”. Refer-
ences of retrieved studieswere searchedmanually for additional studies
and reviews.
2. Morphine
The history of opioids is thousands years long. In 1806 Sertürner iso-
lated a pharmacologically active ingredient from a plant and named it
morphine after the god of dreams in Greek mythology, Morpheus [9].
The afﬁnity of opioids to G-protein coupled receptors (opioid recep-
tors μ, κ, δ, and opioid receptor like-1 mediating distinctive actions),
with subsequent activation of endogenous pain-modulating systems is
responsible for the biological effects of morphine [10].
Despite expected relieve of pain and anxiety, morphine also has
several potentially harmful side effects. It may cause hypotension,
tachycardia as well as bradycardia and respiratory depression [11–13].
The activation of the opioid receptors located in the myenteric
plexus and the intestines decreases propulsive motility and secretion
of the gastro-intestinal tract. As a result, inhibition of gastric emptying,
increase in sphincter tone, induction of stationary motor patterns and
blockade of peristalsis ensue [14]. Moreover, nausea and vomiting are
also common side effects of morphine (Fig. 1) [6].
Several authors reported impact of morphine on myocardial infarc-
tion size [15–19]. In an experimental study, morphine administration
before coronary artery occlusion in rats was associated with an increase
in myocardial infarction size as assessed by histological techniques 48 h
later (45.8% of left ventricular area vs. 35.3%, p b 0.05) [15]. On the
other hand, an experiment performed on isolated rat hearts showed
that morphine given at early reperfusion resulted in a decrease in
infarct volume compared to control (9.8 ± 2.5% vs. 30.0 ± 3.7%,
p b 0.001) [16]. This may be related to the mechanism described by
Jang et al. who revealed that activation of the opioid δ receptor results
in a cardioprotective effect, by inhibition of mitochondrial permeability
transition pore opening [17].Fig. 1. The possible route of interaction betweeIn a single center randomized study the addition of morphine infu-
sion to remote ischemic conditioning (RIC) in ST-segment elevation
myocardial infarction (STEMI) patients was associated with a greater
percentage of ST-segment resolution and lower peak troponin I levels
as comparedwith RIC alone [18]. These results suggestive of a potential-
ly important role of morphine in ischemic conditioningwere supported
by observations indicating that the cardioprotective action of ischemic
pre-conditioning is blocked by pre-treatment with the opiate recep-
tor blocker naloxone [19]. Nevertheless, studies conﬁrming beneﬁcial
clinical effects of morphine in patients with myocardial infarction are
lacking. On the contrary, in the CRUSADE (Can Rapid Risk Stratiﬁcation
of Unstable Angina Patients Suppress ADverse Outcomes with Early Im-
plementation of the ACC/AHA guidelines) registry use of morphine
either alone or in combinationwith nitroglycerin for patients presenting
with non-ST-segment elevation acute coronary syndromes (NSTE ACS)
was associated with higher mortality even after risk adjustment and
matching on propensity score for treatment [20]. However, the impact
of morphine on short- and long-term prognosis in ACS patients still re-
mains ambiguous [21].
3. Morphine and clopidogrel
In the CRUSADE registry out of 57,039 high-risk patients with NSTE
ACS treated with clopidogrel, 17,003 (29.8%) patients received mor-
phine within the ﬁrst 24 h following hospital presentation [20]. The
rates of adverse clinical outcomes were higher in patients who received
IV morphine as compared with those who did not. The rate of myocar-
dial infarction was 3.8% vs. 3.0%, death 5.5% vs. 4.7%, and the composite
end point of death or myocardial infarction was 8.5% vs. 7.1%. After
adjustment for differences in baseline characteristics, the rates of
all measured end points, including myocardial infarction (adjusted
odds ratio [OR] 1.34, 95% CI 1.22–1.48), death (adjusted OR 1.48,
95% CI 1.33–1.64), and the composite end point of death or myocardi-
al infarction (adjusted OR 1.44, 95% CI 1.34–1.56), remained signiﬁ-
cantly higher in patients who received IV morphine. The risk of
mortality was consistently higher across all measured subgroups andn morphine and P2Y12 receptor inhibitors.
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Several possible explanations for the higher risk of adverse outcomes
in patients who received IV morphine are to be taken into account.
Morphine can possibly be a marker for suboptimal medical care. It
may indicate sicker patients with ongoing chest pain or with congestive
heart failure and its analgesic effectsmay only serve to blunt the severity
of angina without actually ameliorating the underlying pathophysio-
logic cause of chest pain. Finally, morphine may actually be deleterious
to ACS patients [20].
Iakobishvili et al. presented observations from the Acute Coronary
Syndrome Israeli Survey 2008, including 765 patients with ST-segment
elevation ACS and 993 patients with NSTE ACS treated with clopidogrel.
The adjusted outcomes of matched pairs using a propensity score for IV
narcotics use tended to be better among patients receiving IV narcotics,
however no difference in 95 matched pairs was found in the 30-day
death rate (2.2% vs. 6.3%, p = 0.16) or 30-day combined end point
(15.8% vs. 17.9%, p = 0.7). The authors suggested that IV narcotics are
safe and perhaps even beneﬁcial, if used appropriately [22].
In another observational study deWaha et al. analyzed the impact of
IVmorphine administration prior to PCI on ischemic injury and salvaged
myocardium assessed by cardiac magnetic resonance imaging in 276
patients with STEMI after 600 mg of clopidogrel. IV morphine adminis-
tration was associated with larger infarct size, higher extent of micro-
vascular obstruction and lower myocardial salvage index as compared
with the non-morphine group (all p b 0.05) [23]. These ﬁndings remain
in line with the results of CRUSADE registry and warrant further ran-
domized clinical trials to assess the effect of IV morphine on clinical
outcome.
Zeymer et al. examined the impact of morphine on pharmacody-
namics of clopidogrel in 31 STEMI patients treated with primary PCI.
The platelet reactivity index (PRI)measuredwith the VASP assay in sub-
jects on morphine and without morphine at 2 h after intake of the
clopidogrel loading dose [LD] was 72.8 ± 15.3% and 60.6 ± 26.1% re-
spectively. After 4 h it amounted 59.1 ± 23.1% and 50.8 ± 24.9% [24].
Despite these inconclusive observations from the Acute Coronary
Syndrome Israeli Survey 2008, a strong premise from the CRUSADE reg-
istry regarding the harmful effect of morphine, additionally supported
by the observations by de Waha et al., cannot be ignored [20,22,23].
There is a biologically plausible cause–effect relationship: opiates inhibit
gastric emptyingwhichmay delay absorption and decrease peakplasma
concentrations of oral drugs [25].
A randomized placebo controlled trial in healthy volunteers showed
that co-administration ofmorphine has a negative impact on clopidogrel
pharmacokinetics. Morphine delayed the maximal plasma concentra-
tions of clopidogrel (Tmax: 105 vs. 83min, p=0.025), reduced themax-
imal plasma concentrations of clopidogrel active metabolite (Cmax:
from 171 vs. 113 ng/mL, p = 0.025) and decreased the total exposure
assessed by the area under the plasma concentration-time curve by
34% (16,840 vs. 11,103 ng ∗ h/mL, p = 0.001). The impact of morphine
on the pharmacokinetics of clopidogrel resulted in 2-fold delay in the
time required to maximally inhibit platelet aggregation (3 vs. 1.25 h,
p b 0.001). Residual platelet aggregation remained higher within 1–4 h
after morphine injection (p b 0.005) [26].
These ﬁndings demonstrated a drug–drug interaction betweenmor-
phine and clopidogrel and provide a potential pathophysiological expla-
nation for the clinical observations from the CRUSADE registry. Hobl
et al. concluded that co-administration of morphine and clopidogrel
should likely be avoided, if possible. More potent P2Y12-inhibitors
may provide greater efﬁcacywhenmorphine is injected, but their inter-
action with morphine should be evaluated in further trials [26].
4. Morphine and novel oral P2Y12 inhibitors
The pharmacodynamic evaluation of loading doses of ticagrelor
(180 mg) and prasugrel (60 mg) revealed near complete inhibition ofADP induced platelet aggregation, with slightly higher maximal inhibi-
tion with prasugrel [27].
Parodi et al. found the following independent predictors of high
platelet reactivity (HPR) 2 h after a 180 mg LD of ticagrelor or 60 mg
LD of prasugrel: morphine use (OR 5.29, 95% CI 1.44–19.49, p = 0.012)
and baseline P2Y12 reaction units (PRU) value (OR 1.014, 95% CI 1.00–
1.03, p = 0.046) [28]. In a subsequent study they conﬁrmed morphine
use (OR 4.49, [1.19–16.88], p = 0.026) and baseline PRU value (OR
1.015, 95% CI 1.00–1.03, p = 0.039) to be predictive of HPR 1 h after a
double LD of ticagrelor (360 mg) or regular 60 mg LD of prasugrel [29].
It has been suggested that, in patients with STEMI, drug absorption is
crucial to the speed of action of oral antiplatelet agents [29,30]. However
caution is neededwhen interpreting these observations due to the small
sample size — the rate of morphine use was identical in both studies
and equaled 9 of 25 patients (36%) treated with ticagrelor [28,29]. The
authors speculated that the observed biological effect of morphine use
is likely related to the inhibition of the normal muscular activity of the
stomach and the intestines, which may lead to vomiting or delayed
drug adsorption. Thus, intravenous antiplatelet agents such as glycopro-
tein IIb/IIIa receptor inhibitors or cangrelor should be considered in
STEMI patients when early platelet inhibition is required. Both studies
provide consistent information suggesting that the onset of action of
oral P2Y12 inhibitors may be delayed by co-administration of mor-
phine [28,29].
To corroborate this hypothesis, a multicenter patient-level inte-
grated analysis from 5 observational studies exploring the effect of
morphine on platelet reactivity in ticagrelor- or prasugrel-treated
STEMI patients undergoing primary PCI was performed [28–33]. Mor-
phine was given according to the decision of attending physicians in
the ambulance or in the emergency room. The study was solely phar-
macodynamic with use of the VerifyNow assay. Patients who received
morphine had higher platelet reactivity at 2 h after the LD of P2Y12
inhibitor (primary end-point) as compared with those without mor-
phine (187.3 vs. 133.7 PRU, p b 0.001, respectively). In ticagrelor-
treated patients, platelet reactivity 2 h after LD was 231 vs. 110 PRU in
those with and without morphine, respectively (p b 0.001). Overall,
HPR (PRU ≥ 208) at 2 h was found in 53% and 29% patients respectively
(p b 0.001), without differences between prasugrel and ticagrelor
groups. The independent predictors of HPR at 2 h were: morphine
use (OR 2.91, 95% CI 1.71–4.97, p b 0.0001) and age (OR 1.03, 95% CI
1.01–1.05, p = 0.010). Morphine remained signiﬁcantly associated
with HPR (OR 1.89, 95% CI 1.40–2.56, p b 0.001) after propensity score
adjustment [31].
These data are consistent with observations of Zeymer et al. The PRI
measured in 19 STEMI patients on morphine and 12 without morphine
at 2 h after the LD of prasugrel was 55.3 ± 31.6 and 42.1 ± 35.4 respec-
tively. After 4 h the difference betweengroups disappeared (39.5±29.5
vs. 38.5 ± 30.4) [24].
Franchi et al. conducted a post-hoc analysis of a randomized study
evaluating escalating loading doses of ticagrelor in 46 patients with
AMI treated with PCI. Patients receiving morphine (35%) had increased
overall platelet reactivity as assessed by the VerifyNow P2Y12 assay in
the ﬁrst 2 h after LD administration (p = 0.047), while no effect was
found between 4 to 24 h (p = 0.78). Parallel ﬁndings were observed
with VASP assay. The pharmacokinetic proﬁle tracked pharmacody-
namic ﬁndings, showing a delay in peak plasma concentrations of both
ticagrelor and AR-C124910XX in patients receivingmorphine, although
the overall drug exposure was similar between groups (receiving and
not receiving morphine) [34].
These data are in line with the results of the ATLANTIC (Administra-
tion of Ticagrelor in the Cath Lab or in the Ambulance for New ST Ele-
vation Myocardial Infarction to Open the Coronary Artery) study [35].
The aim of the ATLANTIC study was to evaluate whether early in-
ambulance administration of ticagrelor could safely improve coronary
reperfusion in patients with STEMI transferred for primary PCI. The pri-
mary end point of ST-segment resolution was signiﬁcantly improved
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receiving morphine (p = 0.005 for interaction). It has been pro-
posed that ticagrelor's onset of action may have been delayed due to
morphine co-administration in half the study population. The extent
to which this interaction may have affected the study results remains
unknown [35].
Silvain et al. reported results of the PRIVATE-ATLANTIC, a prespeciﬁed
substudy of the randomized double blind placebo controlled ATLANTIC
trial. The study population consisted of 37 patients, including 22
(59.5%) of whom received morphine before PCI. Morphine administra-
tion signiﬁcantly delayed the response to ticagrelor as assessed by
VASP-PRI, with a signiﬁcant difference at 1 h after PCI (22.9% vs. 83.2%,
p = 0.003) and 6 h after the loading dose (10.9% vs. 37.6%, p = 0.003).
This effect was more pronounced in the pre-hospital than in the in-
hospital ticagrelor group: 28.5% vs. 82.3%, p = 0.052 at the end of PCI
procedure; 15.7% vs. 69.1%, p = 0.006 at 1 h after PCI; and 6.8% vs.
40.9%, p = 0.02 at 6 h after the loading dose. This observation supports
the hypothesis of an interaction between morphine and oral P2Y12 in-
hibitors and may account for the neutral effect of prehospital treatment
on the primary endpoint in ATLANTIC [36].
Morton et al. performed an open-label, crossover, randomized study
aimed to determine whether morphine delays the onset of action of
prasugrel in patients with previous primary PCI for STEMI. Patients
were randomly assigned to receive either morphine 5 mg or saline
intravenously followed by 60 mg prasugrel. The platelet reactivity,
assessed by the VerifyNow P2Y12 assay were 26 ± 36 PRU with saline
and 104±110 PRUwithmorphine (p=0.027) 2 h after administration
of prasugrel. The response to 20 μM of ADP evaluated with light trans-
mittance aggregometry (LTA) was 5 ± 12% with saline and 23 ± 28%
with morphine (p = 0.033) at 2 h from baseline. These differences in
platelet reactivity disappeared after 24 h (20 ± 27 PRU saline vs.
19 ± 29 PRU morphine). The low number of patients (n = 11) who
completed the study and lack of pharmacokinetic data are itsmajor lim-
itation. The authors concluded that morphine delays prasugrel's onset
of action. Therefore, intravenous drugs may be necessary to reduce theFig. 2. Plasma concentrations of ticagrelor and AR-C124910XX in healthy volunteers and in pa
AR-C124910XX (lower panel) after oral administration of a 180 mg ticagrelor loading dose, w
myocardial infarction and healthy volunteers. Superimposed data from two randomized studrisk of acute stent thrombosis in morphine-treated STEMI patients un-
dergoing primary PCI [37].
The existing body of evidence supports the hypothesis of drug–drug
interaction when morphine and ticagrelor or prasugrel are co-
administered, but until recently there were no data from randomized
combined pharmacokinetic–pharmacodynamic studies in AMI patients
to conﬁrm these alleged interactions.
The IMPRESSION study was the ﬁrst randomized study to conﬁrm
negative impact of morphine on pharmacokinetics and antiplatelet ef-
fects of a novel P2Y12 receptor inhibitor (ticagrelor) in AMI patients.
The IMPRESSION study was a single center, randomized, double-blind,
placebo-controlled trial that assessed the inﬂuence of morphine on
the pharmacokinetics and pharmacodynamics of ticagrelor in 70 pa-
tients with AMI [38]. Morphine infusion lowered the total exposure to
both ticagrelor and its active metabolite (AR-C124910XX) within
the ﬁrst 12 h after administration of the 180 mg ticagrelor LD as com-
pared with placebo (AUC(0–12) of ticagrelor: 6307 ± 4359 vs. 9791 ±
5136 ng ∗ h/mL; corresponding to a difference of 36%; p = 0.003;
AUC(0–12) for AR-C124910XX: 1503 ± 1138 vs. 2388 ± 1555 ng ∗ h/mL;
difference: 37%; p = 0.008) [39]. The maximal plasma concentrations
of ticagrelor in patients receiving morphine were delayed by 2 h as
compared with placebo and reduced (Cmax for ticagrelor: 1156 ± 771
vs. 1683 ± 847 ng/mL; p = 0.006). Morphine administration and the
presence of ST-segment elevation myocardial infarction were indepen-
dent predictors of low AUC(0–12) values in multiple regression analysis.
After adjustment for AMI type (STEMI vs. NSTEMI), a mean decrease in
AUC(0–12) of 3236±1101 ng ∗ h/mLwas found inmorphine-treated pa-
tients as compared with the placebo group (p = 0.005). Assessment of
platelet reactivity showed stronger antiplatelet effect in the placebo
group than in morphine-treated patients [39]. In consequence, the
prevalence of HPR, indicating increased risk of ischemic complications
[40], was higher in the morphine group in the majority of themeasure-
ment points, with the most pronounced difference between 0.5 and
4 h after administration of the LD of ticagrelor. Hence, the observed re-
duction in the antiplatelet effect of ticagrelor was considered to betients with myocardial infarction. Plasma concentrations of ticagrelor (upper panel) and
ith (red) or without (blue) following intravenous injection of morphine in patients with
ies [39,42]. Data present means ± standard error of the mean.
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ﬁndings was not investigated in detail, it seems most likely that
morphine impairs absorption of ticagrelor [39]. Moreover in the sub-
analysis of the IMPRESSION study, we did not ﬁnd any evidence that
the extent of ticagrelor conversion to AR-C124910XX is affected by
morphine administration [41]. Decreased exposure to AR-C124910XX
in the morphine arm compared with the placebo arm of the study
was most likely caused by a proportional attenuation of exposure to
the parent drug.
A recent randomized controlled trial in healthy volunteers gener-
ally conﬁrmed the IMPRESSION ﬁndings [42]. Morphine injection
delayed maximal plasma concentrations of ticagrelor by 1 h and
AR-C124910XX by 2 h. This was associated with reduction of max-
imal plasma concentrations of ticagrelor (from 1222 to 913 ng/mL,
p = 0.015) and AR-C124910XX (from 325 to 242 ng/mL, p = 0.028),
and the total exposure as measured by the AUC0−n by 22%
(p = 0.011) for ticagrelor and 23% (p = 0.009) for its active metab-
olite. However, the impact of morphine on ticagrelor's pharmacody-
namics was not reﬂected by a similar pharmacodynamic effect
assessed by whole blood aggregometry and platelet plug for-
mation under high shear rates. Of note, both assays were maximally
affected by approximately 50% of maximal concentrations of
ticagrelor. This observation suggests that a 180 mg ticagrelor LD
may be potent enough to at least partially overcome the interaction
between oral P2Y12 inhibitors and morphine in stable setting [42],
but not in AMI patients according to results of the IMPRESSION
study [39].
Superimposition of concentration curves from these two ran-
domized studies [39,42] shows general agreement between healthy
volunteers and AMI patients regarding plasma concentration of
ticagrelor and AR-C124910XX. However, considerably higher plasma
concentrations of ticagrelor were observed in AMI patients without
morphine while in healthy volunteers' concentrations of AR-
C124910XX were higher in subjects receiving ticagrelor and morphine
(Fig. 2). On the other hand, as evidenced by the curves of ADP-
induced platelet aggregation, platelet inhibition in healthy volunteers
was deﬁnitely stronger and largely independent of morphine. On the
contrary, in AMI patients the pharmacodynamic effect of ticagrelor
was markedly less pronounced when morphine was co-administeredFig. 3. Platelet reactivity after loading dose of ticagrelor in healthy volunteers and in patients w
180 mg ticagrelor loading dose, with (red) or without (blue) following intravenous injection o
data from two randomized studies [39,42]. Data present means ± standard error of the mean.(Fig. 3). As plasma concentrations of ticagrelor were similar between
healthy subjects and patients with AMI 2 h after co-administration
with morphine, patients with AMI appear to require higher levels
of ticagrelor, likely due to their enhanced platelet activation [43]
(Figs. 2 and 3).
In a further randomized, controlled trial in healthy volunteers, mor-
phine reduced maximal plasma concentrations of prasugrel active me-
tabolite by 31% (p = 0.019), but neither decreased drug exposure nor
altered platelet inhibition [44].
However, results in healthy volunteers may underestimate the true
effect of morphine in patients suffering from myocardial infarction
possibly because of their reduced gastrointestinal perfusion or their
enhanced platelet activation.
5. Clinical implications of morphine–P2Y12 receptor
inhibitors' interaction
The morphine–P2Y12 receptor inhibitors' interaction observed in
numerous trials (Table 1) warrants prompt investigation in clinically
powered randomized trials in the AMI setting. Although the interac-
tion may potentially lead to harmful consequences, routine avoidance
of morphine cannot be recommended until such trials are completed.
Moreover, there is a need to evaluate alternative strategies overcom-
ing or at least diminishing the negative impact of morphine on the
antiplatelet effect of oral P2Y12 receptor inhibitors in AMI patients
including: use of cangrelor, a novel IV P2Y12 receptor inhibitor, or
concomitant administration of a glycoprotein IIb/IIIa receptor inhibitor,
use of a prokinetic agent (e.g., metoclopramide), administration of
crushed ticagrelor tablets and replacement of morphine by a short-
acting analgesic, alfentanil [5,45–47].
6. Conclusions
Morphine delays and attenuates exposure and action of oral
P2Y12 receptor inhibitors in patients with myocardial infarction.
There is a need of further adequately powered randomized trials in-
vestigating the impact of morphine on clinical endpoints in the AMI
setting.ith myocardial infarction. ADP-induced platelet aggregation after oral administration of a
f morphine in patients with myocardial infarction and healthy volunteers. Superimposed
Table 1
Studies regarding morphine–P2Y12 receptor inhibitors' interaction [20,22–24,26,28,29,31,34–37,39,42,44].
Author/acronym Type of the study Aim of the study Study population P2Y12 inhibitor on morphine Decision regarding
morphine
Results regarding interaction P2Y12
inhibitor–morphine
Meine TJ/CRUSADE Retrospective, observational
registry, not focused on
morphine
Evaluation of acute medications and interventions,
in-hospital outcomes, and discharge treatments.
n = 57039
NSTE ACS
Clopidogrel n = 17,003 (30%) According to the
physician's decision
Suspected negative impact on clinical
outcome.
Iakobishvili Z/ACSIS Retrospective, observational
registry, focused on morphine.
Evaluation of the effect of prehospital and in-hospital
IV narcotics use on the in-hospital and 30-day
outcomes among consecutive patients with various
types of ACS.
n = 765 STEMI;
n = 993 NSTE ACS
Clopidogrel n = 261(34%)
STEMI; n = 97 (10%)
NSTE ACS
According to the
physician's decision
Neutral regarding clinical outcome
Parodi G/RAPID Randomized not regarding
morphine
To compare the action of prasugrel and ticagrelor in
STEMI patients undergoing primary PCI.
n = 50 STEMI Ticagrelor n = 9 (36%),
prasugrel n = 12 (48%)
According to the
physician's decision
Suspected negative impact on
pharmacodynamics of ticagrelor and
prasugrel.
Morton AC Randomized regarding
morphine, open-label,
crossover study
To determine whether morphine delays the onset
of action of prasugrel in patients with previous
PPCI for STEMI.
n = 11 post-STEMI Prasugrel n = 11 (100%) Randomization Negative impact on pharmacodynamics
of prasugrel.
Hobl EL Randomized regarding
morphine, double-blind,
placebo-controlled,
cross-over trial
To examine possible drug–drug interaction between
clopidogrel and morphine.
n = 24 healthy
subjects
Clopidogrel n = 24 (100%) Randomization Negative impact on pharmacokinetics and
pharmacodynamics of clopidogrel.
Parodi G/RAPID 2 Randomized not regarding
morphine
To evaluate the impact of increased ticagrelor LD on
platelet inhibition as compared with the standard
prasugrel LD.
n = 50 STEMI Ticagrelor n = 9 (36%),
prasugrel n = 13 (54%)
According to the
physician's decision
Suspected negative impact on
pharmacodynamics of ticagrelor
and prasugrel.
Parodi G Patient-level integrated
analysis of 5 studies
regarding morphine
Assessment of platelet inhibition after LD of
prasugrel/ticagrelor according to morphine use.
n = 300 STEMI Ticagrelor n = 62 (30%),
prasugrel n = 33 (35%)
According to the
physician's decision
Suspected negative impact on
pharmacodynamics of ticagrelor
and prasugrel.
Montalescot/ATLANTIC Randomized not
regarding morphine
To assess whether prehospital administration of
ticagrelor can improve coronary reperfusion and
clinical outcome.
n = 1862 STEMI Ticagrelor n = 800 (43%) According to the
physician's decision
Suspected negative impact on clinical
surrogate end-point.
de Waha S Observational, focused
on morphine.
To analyze the impact of IV morphine on ischemic
injury and salvaged myocardium assessed by cardiac
magnetic resonance imaging in patients with STEMI
reperfused by PPCI.
n = 276 STEMI Clopidogrel n = 123 (45%) According to the
physician's decision
Suspected negative impact on clinical
surrogate end-point.
Franchi F Randomized not regarding
morphine, post-hoc analysis
focused on morphine
To assess the impact of morphine on pharmacokinetic
proﬁles of ticagrelor.
n = 46 AMI Ticagrelor n = 16 (35%) According to the
physician's decision
Suspected negative impact on
pharmacokinetics and
pharmacodynamics of ticagrelor.
Silvain
J/PRIVATE-ATLANTIC
Randomized not regarding
morphine, prespeciﬁed
substudy
To evaluated the impact of morphine administration
on pharmacodynamic and pharmacokinetic effect of
ticagrelor pretreatment
n = 37 STEMI Ticagrelor n = 22 (59%) According to the
physician's decision
Suspected negative impact on
pharmacodynamics of ticagrelor.
Zeymer U/ETAMI Randomized not regarding
morphine
To investigate the inﬂuence of morphine on platelet
inhibition with clopidogrel and prasugrel in patients
with primary PCI
n = 62 STEMI Clopidogrel n = 13 (42%),
prasugrel n = 19 (61%)
According to the
physician's decision
Negative impact on pharmacodynamics of
clopidogrel and prasugrel.
Kubica J/IMPRESSION Randomized regarding
morphine, double-blind,
placebo-controlled study
To assess the inﬂuence of IV morphine on the
pharmacokinetics and pharmacodynamics of
ticagrelor and its active metabolite in AMI patients
n = 70 AMI Ticagrelor n = 35 (50%) Randomization Negative impact on pharmacokinetics and
pharmacodynamics of ticagrelor.
Hobl EL Randomized regarding
morphine, double-blind,
placebo-controlled,
cross-over trial
To examine drug–drug interaction between
morphine and ticagrelor.
n = 24 healthy
subjects
Ticagrelor n = 24 (100%) Randomization Negative impact on pharmacokinetics and
neutral on pharmacodynamics of ticagrelor.
Hobl EL Randomized regarding
morphine, double-blind,
placebo-controlled,
cross-over trial
To examine drug–drug interaction between
morphine and prasugrel.
n = 12 healthy
subjects
Prasugrel n = 12 (100%) Randomization Negative impact on pharmacokinetics and
neutral on pharmacodynamics of prasugrel.
ACS, acute coronary syndromes; AMI, acute myocardial infarction; IV, intravenous; LD, loading dose; NSTE ACS, non-ST elevation acute coronary syndrome; NSTEMI, non-ST elevation myocardial infarction; PCI, percutaneous coronary intervention;
PPCI, primary percutaneous coronary intervention; STEMI, ST elevation myocardial infarction.
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